---
title: "bioAffinity Technologies, Inc. (BIAF.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/BIAF.US.md"
symbol: "BIAF.US"
name: "bioAffinity Technologies, Inc."
industry: "Biotechnology"
---

# bioAffinity Technologies, Inc. (BIAF.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.bioaffinitytech.com](https://www.bioaffinitytech.com) |

## Company Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Servi...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:12.000Z

**Overall: C (0.57)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 171 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -27.66% |  |
| Net Profit YoY | -74.51% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.52 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.67M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 6.78M |  |


**Multi Score**: C

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -245.18% | E |
| Profit Margin | -217.50% | E |
| Gross Margin | 34.84% | C |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -27.66% | E |
| Net Profit YoY | -74.51% | E |
| Total Assets YoY | 76.23% | A |
| Net Assets YoY | 185.23% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -45.98% | D |
| OCF YoY | -27.66% | E |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.75 | B |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 22.90% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - bioAffinity Technologies, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-245.18%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-217.50%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "34.84%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-27.66%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-74.51%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "76.23%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "185.23%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-45.98%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-27.66%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.75",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "22.90%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | Abbvie (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.32 | 118/605 | - | - | - |
| PB | 0.52 | 42/605 | 5.43 | 2.62 | 0.68 |
| PS (TTM) | 0.69 | 11/605 | 1.07 | 0.90 | 0.63 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-08-21T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.04 |

## References

- [Company Overview](https://longbridge.com/en/quote/BIAF.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/BIAF.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/BIAF.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.